HUARONG ENERGY(01101): Delayed announcement of 2025 annual performance

17:31 31/03/2026

Huarong Energy (01101) announced that due to delays in the release of the performance for the 2024 and 2025 mid-year performance, as well as the delivery of related reports, the release of the performance for 2025 and the delivery of the 2025 annual report will also be delayed accordingly. The Board of Directors and management will continue to work closely with auditors to strive for the prompt release of the performance for 2024 and 2025, the 2025 mid-year performance, and related reports.

HUARONG ENERGY (01101) announced that the release of the 2024 annual performance and 2025 mid-year performance, as well as the sending of related reports, have been delayed. As a result, the release of the 2025 annual performance and the sending of the 2025 annual report will also be delayed accordingly. The board of directors and management will continue to work closely with the auditors to strive for the prompt release of the 2024 and 2025 annual performance, the 2025 mid-year performance, and related reports.

Haitian Antenna (08227) disclosed that its net loss attributable to shareholders in 2025 is approximately 8.7124 million yuan, a year-on-year decrease of 45.14%.

ALPHAMAB-B(09966): The Phase III clinical study of KN026 as adjuvant therapy for HER2-positive breast cancer has reached its primary endpoint.

SHOUGANG CENT (00103) released its performance for the year 2025, with a net profit of HK$54.24 million, an increase of 71.4% year-on-year.

Haitian Antenna (08227) disclosed that its net loss attributable to shareholders in 2025 is approximately 8.7124 million yuan, a year-on-year decrease of 45.14%.

ALPHAMAB-B(09966): The Phase III clinical study of KN026 as adjuvant therapy for HER2-positive breast cancer has reached its primary endpoint.

SHOUGANG CENT (00103) released its performance for the year 2025, with a net profit of HK$54.24 million, an increase of 71.4% year-on-year.